COMMUNIQUÉS West-GlobeNewswire

Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
25/07/2024
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company anticipates annualized [...]
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
25/07/2024
- Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody ® ADG126 (muzastotug) with higher, more frequent and repeat dosing in combination with Merck’s anti-PD-1 therapy KEYTRUDA* ( [...]
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
25/07/2024
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and [...]
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
25/07/2024
Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis. 1 This patent strengthens Inventiva’s intellectual property with respect to lanifibranor [...]
Inventiva obtient un nouveau brevet au Japon, élargissant la protection de la propriété intellectuelle de lanifibranor
25/07/2024
► L'Office des brevets japonais a accordé la demande de brevet d'Inventiva concernant l'utilisation de lanifibranor pour le traitement de la cirrhose 1 . ► Ce brevet renforce la propriété intellectuelle d’Inventiva [...]
Cytokinetics to Announce Second Quarter Results on August 8, 2024
25/07/2024
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 8, 2024 at 4:00 PM Eastern Time. [...]
Canadian Red Cross launches appeal for people affected by Alberta Wildfires
25/07/2024
OTTAWA, July 25, 2024 (GLOBE NEWSWIRE) -- The Canadian Red Cross has launched the 2024 Alberta Wildfires Appeal to help people and communities impacted by wildfires in Alberta. Donations to the Canadian Red Cross will [...]
La Croix-Rouge canadienne lance un fonds de secours pour les personnes touchées par les feux de forêt en Alberta
25/07/2024
OTTAWA, 25 juill. 2024 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne a mis sur pied le Fonds de secours : Feux de forêt de 2024 en Alberta afin d’aider les personnes et les communautés touchées par les incendies dans la [...]
BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024
25/07/2024
Los Angeles, CA 90025, July 25, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) or (“BioSig” or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac [...]
Full-Body MRI Innovator Ezra and Longhorn Imaging Partner to Bring Full-Body MRI to Central Texas
25/07/2024
Early cancer detection technology now available for the first time for all Central Texas area residents NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Ezra , a healthcare AI startup revolutionizing early cancer detection [...]
Oxurion Share Consolidation
25/07/2024
Oxurion Share Consolidation Leuven, BELGIUM – July 25, 2024 – 06:00 PM CET Oxurion NV (Euronext Brussels: OXUR) (the Company ), a biopharmaceutical company based in Leuven, announced today that its Board of Directors, [...]
EssilorLuxottica: Q2/H1 2024 Results - Sound revenue growth, margins expanding, two acquisitions in line with strategy
25/07/2024
Q2/H1 2024 Results Sound revenue growth, margins expanding, two acquisitions in line with strategy Revenue growing by 5.2% in Q2 at constant exchange rates 1 , +5.3% in H1 EMEA as the driving region, North America [...]
EssilorLuxottica: Résultats T2/S1 2024 - Solide croissance du chiffre d'affaires, amélioration de la marge, deux acquisitions alignées avec la stratégie du Groupe
25/07/2024
Résultats T2/S1 2024 Solide croissance du chiffre d'affaires, amélioration de la marge, deux acquisitions alignées avec la stratégie du Groupe Hausse du chiffre d’affaires du Groupe de 5,2 % au T2 à taux de change [...]
GUERBET : Chiffre d’affaires du 1er semestre 2024.
25/07/2024
Chiffre d’affaires du 1 er semestre 2024 Activité semestrielle Chiffre d’affaires du 1 er semestre : 419,2 M€, en hausse de 11,8% à TCC 1 , intégrant une accélération au 2 ème trimestre (+14,5%) Cette accélération a été [...]
GUERBET : H1 2024 revenue.
25/07/2024
H1 2024 revenue Half-yearly activity H1 revenue: €419.2m, up 11.8% at CER 1 , including an acceleration in Q2 (+14.5%) This acceleration was driven by continued catch-up in the Americas, the normalisation of orders in [...]
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
25/07/2024
RESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate [...]
European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events
25/07/2024
Bagsværd, Denmark, 25 July 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Wegovy [...]
Press Release: Online availability of Sanofi’s half-year financial report for 2024
25/07/2024
Online availability of Sanofi’s half-year financial report for 2024 Paris, July 25, 2024 . Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available and has been filed [...]
Communiqué de presse : Mise en ligne du rapport financier semestriel 2024 de Sanofi
25/07/2024
Mise en ligne du rapport financier semestriel 2024 de Sanofi Paris, le 25 juillet 2024 . Sanofi annonce aujourd’hui avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers (AMF) son [...]

Pages